<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03250091</url>
  </required_header>
  <id_info>
    <org_study_id>2915</org_study_id>
    <nct_id>NCT03250091</nct_id>
  </id_info>
  <brief_title>Surveillance of Patients With Precancerous Lesions of the Stomach</brief_title>
  <official_title>Surveillance Strategies of Patients With Precancerous Conditions and Lesions in the Stomach</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Latvia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Digestive Diseases Centre Gastro (Latvia)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Riga East University Hospital (Latvia)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Academic Histology Laboratory (Latvia)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Latvia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The project will aim to identify and determine subgroups of patients with different risks of
      progression to gastric cancer and to assess appropriate follow-up intervals. Implementing
      risk stratification only high risk individuals will be offered and performed endoscopic
      surveillance.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Gastric cancer is still an important healthcare problem with significant mortality rates.
      Latvia is a high incidence country of gastric cancer. Unfortunately most of the gastric
      cancer cases in Latvia are diagnosed at late stages when the treatment is substantially less
      effective.

      Ideally, gastric cancer could be prevented by detecting gastric precancerous
      conditions/lesions and identifying those individuals at high-risk of progressing to cancer to
      the follow-up.

      Population based endoscopic screening for gastric cancer is not recommended for the early
      detection of gastric cancer generally deemed not to be cost-effective.

      However, in the absence of screening, patients present with advanced disease, and prognosis
      is poor.

      Targeted endoscopic surveillance strategies for gastric cancer should be introduced following
      the principles of the recent European guidelines: Management of precancerous conditions and
      lesions in the stomach (MAPS) (Dinis-Ribeiro, Areia et al. 2012).

      The project will aim to identify and determine subgroups of patients with different risks of
      progression to gastric cancer and to assess appropriate follow-up intervals. Implementing
      risk stratification only high risk individuals will be offered endoscopic surveillance.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 19, 2017</start_date>
  <completion_date type="Anticipated">December 2027</completion_date>
  <primary_completion_date type="Anticipated">May 2027</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Risk stratification</measure>
    <time_frame>At baseline</time_frame>
    <description>The patients with material of standardized biopsies according to the standard criteria (updated Sydney system) will be classified in different risk groups for progressing to gastric cancer.
The measurements for the risk stratification will be used following the updated Sydney grading and classification system e.g. degree and extent of atrophy, intestinal metaplasia and dysplasia in the stomach mucosa</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Scheduled follow-up procedures (gastroscopies) for high risk group patients</measure>
    <time_frame>At baseline and then 1 and 3 years after the intervention depending on hystopathological report through study completion</time_frame>
    <description>The subgroup of patients at different risk of progression to gastric cancer will be selected and appropriate follow-up intervals will be scheduled and performed. Significant risk stage changes before and after the follow-up upper endoscopy in different research groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastric, faecal microbiome in cancer patients and patients with precancerous lesions</measure>
    <time_frame>At baseline and then 1 and 3 years after the intervention depending on hystopathological report through study completion</time_frame>
    <description>Significant differences in the composition of gastric, faecal microbiome (phyla, genera) in cancer patients and patients with precancerous lesions</description>
  </secondary_outcome>
  <number_of_groups>7</number_of_groups>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Gastric Cancer</condition>
  <condition>Gastric Intestinal Metaplasia</condition>
  <condition>Gastric Atrophy</condition>
  <condition>Gastric Dysplasia</condition>
  <arm_group>
    <arm_group_label>Gastric cancer</arm_group_label>
    <description>Gastric adenocarcinoma and other gastric malignancies</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gastric mucosal dysplasia</arm_group_label>
    <description>Includes: a. High-grade dysplasia; b. Low-grade dysplasia; c. Indefinite for dysplasia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High-risk IM gastritis stages</arm_group_label>
    <description>High-risk stages according to OLGIM classification: OLGIM Stage IV and OLGIM Stage III.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High-risk atrophic gastritis stages</arm_group_label>
    <description>High-risk stages according to OLGA classification: OLGA Stage IV and OLGA Stage III.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Extensive gastric intestinal metaplasia</arm_group_label>
    <description>Intestinal metaplasia of any grade both in gastric corpus and antrum/incisura (other than OLGIM III-IV).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Extensive atrophy</arm_group_label>
    <description>Moderate to severe (++ or +++) atrophy both in corpus and antrum/incisura, other than OLGA III-IV.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Isolated corpus atrophy</arm_group_label>
    <description>Isolated moderate-to-severe atrophy or IM in the corpus.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Upper endoscopy with biopsies</intervention_name>
    <description>Upper endoscopy with proper biopsy work-up will be used for identification and stratification of gastric lesions as well as acquisition of biopsies for histopathological examination, including H.pylori detection</description>
    <arm_group_label>Gastric cancer</arm_group_label>
    <arm_group_label>Gastric mucosal dysplasia</arm_group_label>
    <arm_group_label>High-risk IM gastritis stages</arm_group_label>
    <arm_group_label>High-risk atrophic gastritis stages</arm_group_label>
    <arm_group_label>Extensive gastric intestinal metaplasia</arm_group_label>
    <arm_group_label>Extensive atrophy</arm_group_label>
    <arm_group_label>Isolated corpus atrophy</arm_group_label>
    <other_name>gastroscopy, upper endoscopy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Plasma/serum sampling</intervention_name>
    <description>Plasma/serum sampling will be used to obtain information for group stratification, e.g. H.pylori status determination, serum biomarkers</description>
    <arm_group_label>Gastric cancer</arm_group_label>
    <arm_group_label>Gastric mucosal dysplasia</arm_group_label>
    <arm_group_label>High-risk IM gastritis stages</arm_group_label>
    <arm_group_label>High-risk atrophic gastritis stages</arm_group_label>
    <arm_group_label>Extensive gastric intestinal metaplasia</arm_group_label>
    <arm_group_label>Extensive atrophy</arm_group_label>
    <arm_group_label>Isolated corpus atrophy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Biopsies for gastric microbiota</intervention_name>
    <description>During upper endoscopy biopsies for gastric microbiota analysis will be obtained</description>
    <arm_group_label>Gastric cancer</arm_group_label>
    <arm_group_label>Gastric mucosal dysplasia</arm_group_label>
    <arm_group_label>High-risk IM gastritis stages</arm_group_label>
    <arm_group_label>High-risk atrophic gastritis stages</arm_group_label>
    <arm_group_label>Extensive gastric intestinal metaplasia</arm_group_label>
    <arm_group_label>Extensive atrophy</arm_group_label>
    <arm_group_label>Isolated corpus atrophy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Faecal sample acquisition</intervention_name>
    <description>Faecal samples will be obtained for faecal occult blood testing as well as microbiota analysis</description>
    <arm_group_label>Gastric cancer</arm_group_label>
    <arm_group_label>Gastric mucosal dysplasia</arm_group_label>
    <arm_group_label>High-risk IM gastritis stages</arm_group_label>
    <arm_group_label>High-risk atrophic gastritis stages</arm_group_label>
    <arm_group_label>Extensive gastric intestinal metaplasia</arm_group_label>
    <arm_group_label>Extensive atrophy</arm_group_label>
    <arm_group_label>Isolated corpus atrophy</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Human biopsy samples that are used for histopathology analysis are containing human DNA
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The patients with material of standardized biopsies according to the standard criteria
        (updated Sydney system) will be classified in different risk groups for progression to
        gastric cancer (Group 2-7).

        The appropriate follow-up intervals will be scheduled according MAPS guidelines and
        follow-up procedures (upper endoscopies) will be performed for each research group (Group
        2-7).
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients undergoing upper endoscopy Motivation to participate in the study Signed consent

        Exclusion Criteria:

        Known gastric cancer Unwillingness or inability to co-operate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marcis Leja, Prof.,PhD</last_name>
    <role>Study Director</role>
    <affiliation>Institute of Clinical and Preventive Medicine, University of Latvia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ilze Kikuste, PhD</last_name>
    <phone>28357349</phone>
    <phone_ext>+371</phone_ext>
    <email>ikikuste@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Latvia</name>
      <address>
        <city>Riga</city>
        <zip>LV 1586</zip>
        <country>Latvia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ilze Kikuste, PhD</last_name>
      <phone>+317 28357349</phone>
      <email>ikikuste@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Marcis Leja, Prof., PhD</last_name>
      <email>marcis.leja@lu.lv</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Latvia</country>
  </location_countries>
  <reference>
    <citation>Dinis-Ribeiro M, Areia M, de Vries AC, Marcos-Pinto R, Monteiro-Soares M, O'Connor A, Pereira C, Pimentel-Nunes P, Correia R, Ensari A, Dumonceau JM, Machado JC, Macedo G, Malfertheiner P, Matysiak-Budnik T, Megraud F, Miki K, O'Morain C, Peek RM, Ponchon T, Ristimaki A, Rembacken B, Carneiro F, Kuipers EJ; European Society of Gastrointestinal Endoscopy; European Helicobacter Study Group; European Society of Pathology; Sociedade Portuguesa de Endoscopia Digestiva. Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED). Endoscopy. 2012 Jan;44(1):74-94. doi: 10.1055/s-0031-1291491. Epub 2011 Dec 23.</citation>
    <PMID>22198778</PMID>
  </reference>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 21, 2017</study_first_submitted>
  <study_first_submitted_qc>August 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 15, 2017</study_first_posted>
  <last_update_submitted>August 14, 2017</last_update_submitted>
  <last_update_submitted_qc>August 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>gastric precancerous lesions</keyword>
  <keyword>gastric cancer</keyword>
  <keyword>gastric intestinal Metaplasia</keyword>
  <keyword>gastric atrophy</keyword>
  <keyword>gastric dysplasia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Atrophy</mesh_term>
    <mesh_term>Metaplasia</mesh_term>
    <mesh_term>Gastritis, Atrophic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

